stella
beta
RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies — Stella
Recruiting
Back to NK T-Cell Lymphoma trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
China
Union Hospital, Wuhan, Hubei
View full record on ClinicalTrials.gov